Conjugation with S4 protein transduction domain enhances the immunogenicity of the peptide vaccine against breast cancer

Moore,Jayla A.; Ali,Umer; Vungarala,Sunitha; Young‑Seigler,Artenzia; Tiriveedhi,Venkataswarup

doi:10.3892/mco.2024.2815

Conjugation with S4 protein transduction domain enhances the immunogenicity of the peptide vaccine against breast cancer

Authors:
- Jayla A. Moore
- Umer Ali
- Sunitha Vungarala
- Artenzia Young‑Seigler
- Venkataswarup Tiriveedhi
View Affiliations

Affiliations: Department of Biological Sciences, Tennessee State University, Nashville, TN 37209, USA, Department of Population Sciences, Meharry‑Vanderbilt Alliance, Nashville, TN 37208, USA
Published online on: December 13, 2024 https://doi.org/10.3892/mco.2024.2815
Article Number: 20
Copyright: © Moore et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although peptide vaccines offer a novel venue for cancer immunotherapy, clinical success has been rather limited. Cell‑penetrating peptides, due to their ability to translocate through the cell membrane, could be conjugated to the peptide vaccine to enhance therapeutic efficiency. The S4 transduction domain of the shaker‑potassium channel was conjugated to mammaglobin‑A (MamA) immunodominant epitope (MamA2.1) to verify its anticancer immunogenicity. S4‑MamA2.1 peptide has demonstrated significantly higher epitope loading and stable membrane expression of HLA‑A2 antigen‑presenting molecules on T2 cell lines. Further, these S4‑MamA2.1 treated T2 cells were able to activate naïve CD8+ T cells to induce MamA‑specific cytotoxicity against breast cancer cells. Conjugation of the S4 domain has also demonstrated a slight increase in immunogenicity of lesser immunodominant MamA epitopes. The conjugation of the S4 domain to N‑terminus of MamA2.1 demonstrated significantly higher immunogenicity over C‑terminus conjugation. Taken together, the results of the present study suggest that conjugation of the S4 cell‑penetrating peptide domain to MamA2.1 epitope enhances the peptide vaccine immunogenicity against MamA‑expressing breast cancers.

View Figures

View References

1	Siegel RL, Giaquinto AN and Jemal A: Cancer statistics, 2024. CA Cancer J Clin. 74:12–49. 2024.PubMed/NCBI View Article : Google Scholar
2	Brufsky A, Kwan ML, Sandin R, Stergiopoulos S, Karanth S, Cha-Silva AS, Makari D and Goyal RK: Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: A SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer. Breast Cancer Res Treat. 208:223–235. 2024.PubMed/NCBI View Article : Google Scholar
3	Sotirov S and Dimitrov I: Tumor-derived antigenic peptides as potential cancer vaccines. Int J Mol Sci. 25(4934)2024.PubMed/NCBI View Article : Google Scholar
4	Curigliano G, Bagnardi V, Ghioni M, Louahed J, Brichard V, Lehmann FF, Marra A, Trapani D, Criscitiello C and Viale G: Expression of tumor-associated antigens in breast cancer subtypes. Breast. 49:202–209. 2020.PubMed/NCBI View Article : Google Scholar
5	Liu Z, Yang X, Duan C, Li J, Tong R, Fan Y, Feng J, Cao R, Zhong W, Feng X, et al: Identification and characterization of mammaglobin-A epitope in heterogenous breast cancers for enhancing tumor-targeting therapy. Signal Transduct Target Ther. 5(82)2020.PubMed/NCBI View Article : Google Scholar
6	Milosevic B, Stojanovic B, Cvetkovic A, Jovanovic I, Spasic M, Stojanovic MD, Stankovic V, Sekulic M, Stojanovic BS, Zdravkovic N, et al: The enigma of mammaglobin: Redefining the biomarker paradigm in breast carcinoma. Int J Mol Sci. 24(13407)2023.PubMed/NCBI View Article : Google Scholar
7	Li G, Zhang J, Jin K, He K, Wang H, Lu H and Teng L: Human mammaglobin: A superior marker for reverse-transcriptase PCR in detecting circulating tumor cells in breast cancer patients. Biomark Med. 5:249–260. 2011.PubMed/NCBI View Article : Google Scholar
8	O'Brien N, Maguire TM, O'Donovan N, Lynch N, Hill AD, McDermott E, O'Higgins N and Duffy MJ: Mammaglobin a: A promising marker for breast cancer. Clin Chem. 48:1362–1364. 2002.PubMed/NCBI
9	Tiriveedhi V, Tucker N, Herndon J, Li L, Sturmoski M, Ellis M, Ma C, Naughton M, Lockhart AC, Gao F, et al: Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer. Clin Cancer Res. 20:5964–5975. 2014.PubMed/NCBI View Article : Google Scholar
10	Jaramillo A, Narayanan K, Campbell LG, Benshoff ND, Lybarger L, Hansen TH, Fleming TP, Dietz JR and Mohanakumar T: Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Breast Cancer Res Treat. 88:29–41. 2004.PubMed/NCBI View Article : Google Scholar
11	Babaer D, Amara S, McAdory BS, Johnson O, Myles EL, Zent R, Rathmell JC and Tiriveedhi V: Oligodeoxynucleotides ODN 2006 and M362 exert potent adjuvant effect through TLR-9/-6 synergy to exaggerate mammaglobin-A peptide specific cytotoxic CD8+T lymphocyte responses against breast cancer cells. Cancers (Basel). 11(672)2019.PubMed/NCBI View Article : Google Scholar
12	Babaer D, Zheng M, Ivy MT, Zent R and Tiriveedhi V: Methylselenol producing selenocompounds enhance the efficiency of mammaglobin-A peptide vaccination against breast cancer cells. Oncol Lett. 18:6891–6898. 2019.PubMed/NCBI View Article : Google Scholar
13	Nelde A, Rammensee HG and Walz JS: The peptide vaccine of the future. Mol Cell Proteomics. 20(100022)2021.PubMed/NCBI View Article : Google Scholar
14	Xie N, Shen G, Gao W, Huang Z, Huang C and Fu L: Neoantigens: Promising targets for cancer therapy. Signal Transduct Target Ther. 8(9)2023.PubMed/NCBI View Article : Google Scholar
15	Nguyen AT, Szeto C and Gras S: The pockets guide to HLA class I molecules. Biochem Soc Trans. 49:2319–2331. 2021.PubMed/NCBI View Article : Google Scholar
16	Moynihan KD, Holden RL, Mehta NK, Wang C, Karver MR, Dinter J, Liang S, Abraham W, Melo MB, Zhang AQ, et al: Enhancement of peptide vaccine immunogenicity by increasing lymphatic drainage and boosting serum stability. Cancer Immunol Res. 6:1025–1038. 2018.PubMed/NCBI View Article : Google Scholar
17	Ding Y, Li Z, Jaklenec A and Hu Q: Vaccine delivery systems toward lymph nodes. Adv Drug Deliv Rev. 179(113914)2021.PubMed/NCBI View Article : Google Scholar
18	Kim CG, Kye YC and Yun CH: The role of nanovaccine in cross-presentation of antigen-presenting cells for the activation of CD8(+) T cell responses. Pharmaceutics. 11(612)2019.PubMed/NCBI View Article : Google Scholar
19	Yang J, Luo Y, Shibu MA, Toth I and Skwarczynskia M: Cell-penetrating peptides: Efficient vectors for vaccine delivery. Curr Drug Deliv. 16:430–443. 2019.PubMed/NCBI View Article : Google Scholar
20	Tiriveedhi V and Butko P: A fluorescence spectroscopy study on the interactions of the TAT-PTD peptide with model lipid membranes. Biochemistry. 46:3888–3895. 2007.PubMed/NCBI View Article : Google Scholar
21	Tiriveedhi V, Miller M, Butko P and Li M: Autonomous transmembrane segment S4 of the voltage sensor domain partitions into the lipid membrane. Biochim Biophys Acta. 1818:1698–1705. 2012.PubMed/NCBI View Article : Google Scholar
22	Bossi G, Gerry AB, Paston SJ, Sutton DH, Hassan NJ and Jakobsen BK: Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells. Oncoimmunology. 2(e26840)2013.PubMed/NCBI View Article : Google Scholar
23	Tiriveedhi V, Ivy MT, Myles EL, Zent R, Rathmell JC and Titze J: Ex vivo high salt activated tumor-primed CD4+T lymphocytes exert a potent anti-cancer response. Cancers (Basel). 13(1690)2021.PubMed/NCBI View Article : Google Scholar
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
25	Luft T, Rizkalla M, Tai TY, Chen Q, MacFarlan RI, Davis ID, Maraskovsky E and Cebon J: Exogenous peptides presented by transporter associated with antigen processing (TAP)-deficient and TAP-competent cells: Intracellular loading and kinetics of presentation. J Immunol. 167:2529–2537. 2001.PubMed/NCBI View Article : Google Scholar
26	Zahedipour F, Jamialahmadi K, Zamani P and Jaafari MR: Improving the efficacy of peptide vaccines in cancer immunotherapy. Int Immunopharmacol. 123(110721)2023.PubMed/NCBI View Article : Google Scholar
27	Stephens AJ, Burgess-Brown NA and Jiang S: Beyond just peptide antigens: The complex world of peptide-based cancer vaccines. Front Immunol. 12(696791)2021.PubMed/NCBI View Article : Google Scholar
28	Bottens RA and Yamada T: Cell-Penetrating peptides (CPPs) as therapeutic and diagnostic agents for cancer. Cancers (Basel). 14(5546)2022.PubMed/NCBI View Article : Google Scholar
29	Hasannejad-Asl B, Pooresmaeil F, Takamoli S, Dabiri M and Bolhassani A: Cell penetrating peptide: A potent delivery system in vaccine development. Front Pharmacol. 13(1072685)2022.PubMed/NCBI View Article : Google Scholar
30	Buonaguro L and Tagliamonte M: Peptide-based vaccine for cancer therapies. Front Immunol. 14(1210044)2023.PubMed/NCBI View Article : Google Scholar
31	Wu X, Li T, Jiang R, Yang X, Guo H and Yang R: Targeting MHC-I molecules for cancer: Function, mechanism, and therapeutic prospects. Mol Cancer. 22(194)2023.PubMed/NCBI View Article : Google Scholar
32	Backlund CM, Holden RL, Moynihan KD, Garafola D, Farquhar C, Mehta NK, Maiorino L, Pham S, Iorgulescu JB, Reardon DA, et al: Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity. Proc Natl Acad Sci USA. 119(e2204078119)2022.PubMed/NCBI View Article : Google Scholar